Inotek Pharmaceuticals Corporation (ITEK) 5.61 $ITEK
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 4:39PM CDT
MXIM: 32.78 (-1.96), AMZN: 445.10 (+55.11), GIMO: 29.75 (+6.16), AMSC: 6.88 (-3.12), UBNT: 31.29 (-0.14), AWAY: 27.18 (-4.99), ALGN: 59.18 (+3.17), ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52), RIGL: 4.88 (+0.55)
Floats Stumble In Q1 As Bubble Debate Escalates
EP Vantage - Seeking Alpha - Mon Apr 13, 1:15PM CDT
In the “it is/is not a bubble” debate, those arguing “is” have a data point on their side with the news that first-quarter biopharma flotation totals were among the most disappointing in two years. It might be too soon to...
GILD: 103.69 (-1.52), ITEK: 5.61 (+0.86), ONCE: 61.39 (-0.66), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98)
Horizon Technology Finance Provides Investment Portfolio Update for First Quarter 2015
GlobeNewswire - Wed Apr 08, 3:15PM CDT
Horizon Technology Finance Corporation (Nasdaq:HRZN) ("Horizon"
, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services and cleantech industries, today provided a portfolio update for the first quarter of 2015.
ITEK: 5.61 (+0.86), HRZN: 14.30 (+0.06)
Inotek Pharmaceuticals FY14 results
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:34AM CDT
ITEK: 5.61 (+0.86)
Inotek Pharmaceuticals reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:06AM CDT
ITEK: 5.61 (+0.86)
Inotek Pharmaceuticals Corporation Reports 2014 Financial Results
Business Wire - Wed Apr 01, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the "Company" , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma, today reported financial results and operational highlights for the year ended December 31, 2014.
ITEK: 5.61 (+0.86)
Hercules Reports Solid Q1 Originations; Gives 2015 Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 9:20AM CDT
Hercules (HTGC) released its portfolio update for first-quarter 2015, which continued to reflect sturdy loan origination performance.
BOX: 17.75 (-0.53), HTGC: 13.97 (-0.09), ITEK: 5.61 (+0.86), ZSAN: 8.80 (-0.10)
Hercules Announces Interim Portfolio Update for Q1 2015
Business Wire - Mon Mar 16, 2:11PM CDT
--Surpasses $5.0 Billion Milestone in Debt Commitments Since Inception (December 2003)
HTGC: 13.97 (-0.09), BOX: 17.75 (-0.53), ITEK: 5.61 (+0.86), ZSAN: 8.80 (-0.10)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 295.41 (-2.95), PCYC: 256.59 (-0.51), ITEK: 5.61 (+0.86), REDX: (), PTX: 7.09 (-0.24), CLDX: 30.10 (+0.19), ILMN: 189.59 (-3.01), IDGX: (), ACAD: 38.36 (-0.54), TRGT: 2.43 (+0.04), CLLS: 32.61 (-0.07), EXAC: 24.40 (+0.15), ABBV: 66.07 (+1.82), CRMD: 8.61 (-0.22), AGMX: (), ZGNX: 1.54 (-0.11), VVUS: 2.46 (-0.04), SPPI: 6.10 (+0.07), GSK: 46.59 (+0.28), OREX: 7.36 (-0.08), SQNM: 4.52 (-0.10), IRWD: 15.10 (-0.38), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), OHRP: 2.94 (+0.12), TEVA: 64.41 (+1.16)
Inotek: Tepid IPO Only Postpones Existential Threat And Significantly Delays Product Launch
Northern Fundamentals - at Seeking Alpha - Fri Mar 13, 4:00AM CDT
ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52)
U.S. IPO Weekly Recap: No IPOs In Final Week Of A Challenging February
Renaissance Capital IPO Research - at Seeking Alpha - Tue Mar 03, 11:15AM CST
There were no initial public offerings in the past week, but recent IPO performance continues to trend up. The 24 IPOs in 2015 now average +18%, including +5% after the first day, its highest point this year. A few highlights from February 2015: ...
CHEKU: 6.01 (unch), ITEK: 5.61 (+0.86), INOV: 26.67 (-0.32), CPPL: 26.52 (-0.39), NVTA: 13.23 (+0.41), AJX: 14.28 (unch)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.73 (-0.01), NBIX: 43.37 (-0.31), ITEK: 5.61 (+0.86), ARIA: 9.71 (+0.10), ARRY: 7.19 (-0.12)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.17 (+0.02), AGN: 240.22 (+2.88), ACAD: 38.36 (-0.54), ITEK: 5.61 (+0.86), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), FOMX: 10.46 (-0.44), AERI: 12.87 (-22.52), CBMG: 29.51 (-1.85)
Hercules Announces Fourth Quarter and Full-Year 2014 Financial Results and Quarterly Dividend of $0.31 per Share
Business Wire - Mon Mar 02, 5:21PM CST
--Spillover Taxable Income (taxable income in excess of dividends paid) as of December 31, 2014 of ~$16.7 million, or ~$0.27 per share
HTGC: 13.97 (-0.09), BOX: 17.75 (-0.53), ITEK: 5.61 (+0.86), NEOT: 7.48 (-0.07), ZSAN: 8.80 (-0.10), Z: 98.26 (-1.61)
InsiderInsights.com Daily Round Up 2/25/15: ASYS, MRC, CRR, ALCO
InsiderInsights - at Seeking Alpha - Thu Feb 26, 12:23PM CST
CRR: 31.60 (-1.26), ITEK: 5.61 (+0.86), KFRC: 22.07 (+0.04), ORLY: 229.35 (+1.04), MRC: 13.76 (-0.28), WETF: 21.08 (-0.48), MLNK: 3.66 (-0.05), AWI: 57.97 (+0.78), ASYS: 12.04 (-0.16), GHC: 1,068.39 (+1.95), GOOG: 565.06 (+18.06), ARMK: 31.66 (+0.20), DTV: 89.85 (-0.27), MIDD: 103.17 (-0.52), DD: 71.52 (+0.73), ALCO: 47.11 (-0.65)
Inotek Pharma finalizes IPO
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 3:47PM CST
ITEK: 5.61 (+0.86)
U.S. IPO Weekly Recap: Health IPOs Go Public Or Postpone Ahead Of A Busy March
Renaissance Capital IPO Research - at Seeking Alpha - Sun Feb 22, 4:46AM CST
This past week, the set of small health IPOs that had been languishing on the IPO calendar either postponed or went public. • Two small health IPOs raised a combined $52 million • Two small health IPOs postponed indefinitely • Just...
WOWO: 9.35 (+0.51), VIRT: 22.16 (-0.44), CHEK: 4.24 (+0.03), ITEK: 5.61 (+0.86)
Inotek Pharma prices IPO at a significant discount to original plan
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 6:50AM CST
ITEK: 5.61 (+0.86)
Inotek Pharmaceuticals Corporation Announces Pricing of Initial Public Offering of 6,667,000 Shares of Common Stock and 5.0% Convertible Senior Notes due 2020
Business Wire - Wed Feb 18, 4:00AM CST
Inotek Pharmaceuticals Corporation (the "Company" today announced the pricing of its initial public offering of 6,667,000 shares of its common stock at a price to the public of $6.00 per share for aggregate proceeds of $40 million, before underwriting discounts. All of the common stock is being offered by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,000,050 shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Global Market today under the symbol "ITEK."
ITEK: 5.61 (+0.86)
U.S. IPO Weekly Recap: Big Data Produces Small Returns In A Selective IPO Market
Renaissance Capital IPO Research - Seeking Alpha - Sat Feb 14, 11:07PM CST
Five companies had below-average returns and brought the number of 2015 IPOs up to 22, a 39% decline from this time last year... • 5 of 12 IPOs got done ; 2nd week in a row where less than half of possible deals priced •Even as the IPO...
IDGX: (), AGMX: (), SLWD: (), ITEK: 5.61 (+0.86), REDX: (), AVNU: 11.94 (+0.29), INOV: 26.67 (-0.32), CBYL: 7.45 (-0.11), NVTA: 13.23 (+0.41), AJX: 14.28 (unch), BLPH: 9.53 (-0.39)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 4:39PM CDT
MXIM: 32.78 (-1.96), AMZN: 445.10 (+55.11), GIMO: 29.75 (+6.16), AMSC: 6.88 (-3.12), UBNT: 31.29 (-0.14), AWAY: 27.18 (-4.99), ALGN: 59.18 (+3.17), ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52), RIGL: 4.88 (+0.55)
Floats Stumble In Q1 As Bubble Debate Escalates
EP Vantage - Seeking Alpha - Mon Apr 13, 1:15PM CDT
In the “it is/is not a bubble” debate, those arguing “is” have a data point on their side with the news that first-quarter biopharma flotation totals were among the most disappointing in two years. It might be too soon to...
GILD: 103.69 (-1.52), ITEK: 5.61 (+0.86), ONCE: 61.39 (-0.66), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98)
Horizon Technology Finance Provides Investment Portfolio Update for First Quarter 2015
GlobeNewswire - Wed Apr 08, 3:15PM CDT
Horizon Technology Finance Corporation (Nasdaq:HRZN) ("Horizon"
, a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services and cleantech industries, today provided a portfolio update for the first quarter of 2015. ITEK: 5.61 (+0.86), HRZN: 14.30 (+0.06)
Inotek Pharmaceuticals FY14 results
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:34AM CDT
ITEK: 5.61 (+0.86)
Inotek Pharmaceuticals reports Q4 results
Seeking Alpha - at Seeking Alpha - Wed Apr 01, 6:06AM CDT
ITEK: 5.61 (+0.86)
Inotek Pharmaceuticals Corporation Reports 2014 Financial Results
Business Wire - Wed Apr 01, 6:00AM CDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the "Company"
, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma, today reported financial results and operational highlights for the year ended December 31, 2014. ITEK: 5.61 (+0.86)
Hercules Reports Solid Q1 Originations; Gives 2015 Target - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 17, 9:20AM CDT
Hercules (HTGC) released its portfolio update for first-quarter 2015, which continued to reflect sturdy loan origination performance.
BOX: 17.75 (-0.53), HTGC: 13.97 (-0.09), ITEK: 5.61 (+0.86), ZSAN: 8.80 (-0.10)
Hercules Announces Interim Portfolio Update for Q1 2015
Business Wire - Mon Mar 16, 2:11PM CDT
--Surpasses $5.0 Billion Milestone in Debt Commitments Since Inception (December 2003)
HTGC: 13.97 (-0.09), BOX: 17.75 (-0.53), ITEK: 5.61 (+0.86), ZSAN: 8.80 (-0.10)
Seeking Alpha's Biotech Weekly: Deeper Looks At Orexigen, Pharmacyclics, And Acadia
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 13, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
ACT: 295.41 (-2.95), PCYC: 256.59 (-0.51), ITEK: 5.61 (+0.86), REDX: (), PTX: 7.09 (-0.24), CLDX: 30.10 (+0.19), ILMN: 189.59 (-3.01), IDGX: (), ACAD: 38.36 (-0.54), TRGT: 2.43 (+0.04), CLLS: 32.61 (-0.07), EXAC: 24.40 (+0.15), ABBV: 66.07 (+1.82), CRMD: 8.61 (-0.22), AGMX: (), ZGNX: 1.54 (-0.11), VVUS: 2.46 (-0.04), SPPI: 6.10 (+0.07), GSK: 46.59 (+0.28), OREX: 7.36 (-0.08), SQNM: 4.52 (-0.10), IRWD: 15.10 (-0.38), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), OHRP: 2.94 (+0.12), TEVA: 64.41 (+1.16)
Inotek: Tepid IPO Only Postpones Existential Threat And Significantly Delays Product Launch
Northern Fundamentals - at Seeking Alpha - Fri Mar 13, 4:00AM CDT
ITEK: 5.61 (+0.86), AERI: 12.87 (-22.52)
U.S. IPO Weekly Recap: No IPOs In Final Week Of A Challenging February
Renaissance Capital IPO Research - at Seeking Alpha - Tue Mar 03, 11:15AM CST
There were no initial public offerings in the past week, but recent IPO performance continues to trend up. The 24 IPOs in 2015 now average +18%, including +5% after the first day, its highest point this year. A few highlights from February 2015: ...
CHEKU: 6.01 (unch), ITEK: 5.61 (+0.86), INOV: 26.67 (-0.32), CPPL: 26.52 (-0.39), NVTA: 13.23 (+0.41), AJX: 14.28 (unch)
Early Briefing on Biotech Industry Stocks -- ARIAD Pharma, Array BioPharma, Rexahn Pharma, Inotek Pharma, and Neurocrine Biosciences
PR Newswire - Tue Mar 03, 7:40AM CST
Editor Note: For more information about this release, please scroll to bottom.
RNN: 0.73 (-0.01), NBIX: 43.37 (-0.31), ITEK: 5.61 (+0.86), ARIA: 9.71 (+0.10), ARRY: 7.19 (-0.12)
Glaucoma - Pipeline Review, H1 2015 - Featuring 50 Companies & 104 Drug Profiles
M2 - Tue Mar 03, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/8h3k7s/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AC Immune SA - Acadia Pharmaceuticals Inc. - Aerie Pharmaceuticals, Inc. - Alcon, Inc. - Allergan, Inc. - Altacor Ltd. - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Can-Fite BioPharma Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Handok Inc. - High Point Pharmaceuticals, LLC - Icon Bioscience, Inc. - IMMD Inc. - Inotek Pharmaceuticals Corporation - InSite Vision Incorporated - Lacer, S.A. - Merck & Co., Inc. - Merz Pharma GmbH & Co. KgaA For more information visit http://www.researchandmarkets.com/research/8h3k7s/glaucoma
CANF: 2.17 (+0.02), AGN: 240.22 (+2.88), ACAD: 38.36 (-0.54), ITEK: 5.61 (+0.86), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), FOMX: 10.46 (-0.44), AERI: 12.87 (-22.52), CBMG: 29.51 (-1.85)
Hercules Announces Fourth Quarter and Full-Year 2014 Financial Results and Quarterly Dividend of $0.31 per Share
Business Wire - Mon Mar 02, 5:21PM CST
--Spillover Taxable Income (taxable income in excess of dividends paid) as of December 31, 2014 of ~$16.7 million, or ~$0.27 per share
HTGC: 13.97 (-0.09), BOX: 17.75 (-0.53), ITEK: 5.61 (+0.86), NEOT: 7.48 (-0.07), ZSAN: 8.80 (-0.10), Z: 98.26 (-1.61)
InsiderInsights.com Daily Round Up 2/25/15: ASYS, MRC, CRR, ALCO
InsiderInsights - at Seeking Alpha - Thu Feb 26, 12:23PM CST
CRR: 31.60 (-1.26), ITEK: 5.61 (+0.86), KFRC: 22.07 (+0.04), ORLY: 229.35 (+1.04), MRC: 13.76 (-0.28), WETF: 21.08 (-0.48), MLNK: 3.66 (-0.05), AWI: 57.97 (+0.78), ASYS: 12.04 (-0.16), GHC: 1,068.39 (+1.95), GOOG: 565.06 (+18.06), ARMK: 31.66 (+0.20), DTV: 89.85 (-0.27), MIDD: 103.17 (-0.52), DD: 71.52 (+0.73), ALCO: 47.11 (-0.65)
Inotek Pharma finalizes IPO
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 3:47PM CST
ITEK: 5.61 (+0.86)
U.S. IPO Weekly Recap: Health IPOs Go Public Or Postpone Ahead Of A Busy March
Renaissance Capital IPO Research - at Seeking Alpha - Sun Feb 22, 4:46AM CST
This past week, the set of small health IPOs that had been languishing on the IPO calendar either postponed or went public. • Two small health IPOs raised a combined $52 million • Two small health IPOs postponed indefinitely • Just...
WOWO: 9.35 (+0.51), VIRT: 22.16 (-0.44), CHEK: 4.24 (+0.03), ITEK: 5.61 (+0.86)
Inotek Pharma prices IPO at a significant discount to original plan
Seeking Alpha - at Seeking Alpha - Wed Feb 18, 6:50AM CST
ITEK: 5.61 (+0.86)
Inotek Pharmaceuticals Corporation Announces Pricing of Initial Public Offering of 6,667,000 Shares of Common Stock and 5.0% Convertible Senior Notes due 2020
Business Wire - Wed Feb 18, 4:00AM CST
Inotek Pharmaceuticals Corporation (the "Company"
today announced the pricing of its initial public offering of 6,667,000 shares of its common stock at a price to the public of $6.00 per share for aggregate proceeds of $40 million, before underwriting discounts. All of the common stock is being offered by the Company. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,000,050 shares of common stock to cover over-allotments, if any. The shares are expected to begin trading on the NASDAQ Global Market today under the symbol "ITEK." ITEK: 5.61 (+0.86)
U.S. IPO Weekly Recap: Big Data Produces Small Returns In A Selective IPO Market
Renaissance Capital IPO Research - Seeking Alpha - Sat Feb 14, 11:07PM CST
Five companies had below-average returns and brought the number of 2015 IPOs up to 22, a 39% decline from this time last year... • 5 of 12 IPOs got done ; 2nd week in a row where less than half of possible deals priced •Even as the IPO...
IDGX: (), AGMX: (), SLWD: (), ITEK: 5.61 (+0.86), REDX: (), AVNU: 11.94 (+0.29), INOV: 26.67 (-0.32), CBYL: 7.45 (-0.11), NVTA: 13.23 (+0.41), AJX: 14.28 (unch), BLPH: 9.53 (-0.39)
